Unlocking the secrets of amyloid

Since the 1970s Dr. Robert Kisilevsky (photo, left) of Queen’s University has worked to broaden scientific understanding of abnormal protein structures known as amyloids. These needle-like deposits in tissues interfere with cell function and are associated with a number of diseases, including Alzheimer’s and adult-onset diabetes. Searching for a way to interfere with the molecular formation of one particular form of amyloid, Dr. Kisilevsky began collaborating with Queen’s chemist Dr. Walter Szarek (photo, right) in the 1980s.

The Queen’s researchers’ investigations of the mechanisms that form these deposits, and the formulation of compounds to block and remove them, led to the formation of Neurochem Inc., a leading Canadian biotechnology company that continues to advance the commercial development of this breakthrough research.

Meanwhile, Dr. Kisilevsky’s research into the relationship between amyloid and cholesterol accumulation has resulted in the formation of a second Canadian company, AtheroChem Inc., focused on developing novel compounds for the treatment of coronary heart disease caused by atherosclerosis.

http://www.path.queensu.ca/queens/fac/kisil.htm

http://www.chem.queensu.ca/people/faculty/Szarek/

Photo: Colin Rowe